Literature DB >> 18851683

Epigenetics, DNA methylation, and chromatin modifying drugs.

Moshe Szyf1.   

Abstract

Evidence is emerging that several diseases and behavioral pathologies result from defects in gene function. The best-studied example is cancer, but other diseases such as autoimmune disease, asthma, type 2 diabetes, metabolic disorders, and autism display aberrant gene expression. Gene function may be altered by either a change in the sequence of the DNA or a change in epigenetic programming of a gene in the absence of a sequence change. With epigenetic drugs, it is possible to reverse aberrant gene expression profiles associated with different disease states. Several epigenetic drugs targeting DNA methylation and histone deacetylation enzymes have been tested in clinical trials. Understanding the epigenetic machinery and the differential roles of its components in specific disease states is essential for developing targeted epigenetic therapy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 18851683     DOI: 10.1146/annurev-pharmtox-061008-103102

Source DB:  PubMed          Journal:  Annu Rev Pharmacol Toxicol        ISSN: 0362-1642            Impact factor:   13.820


  133 in total

1.  DNA methylation and memory formation.

Authors:  Jeremy J Day; J David Sweatt
Journal:  Nat Neurosci       Date:  2010-11       Impact factor: 24.884

Review 2.  DNA methylation topology: potential of a chromatin landmark for epigenetic drug toxicology.

Authors:  Jian Tajbakhsh
Journal:  Epigenomics       Date:  2011-12       Impact factor: 4.778

Review 3.  Chemical and biochemical approaches in the study of histone methylation and demethylation.

Authors:  Keqin Kathy Li; Cheng Luo; Dongxia Wang; Hualiang Jiang; Y George Zheng
Journal:  Med Res Rev       Date:  2012-07       Impact factor: 12.944

4.  Epigenetics in mental illness: hope or hype?

Authors:  Paul R Albert
Journal:  J Psychiatry Neurosci       Date:  2010-11       Impact factor: 6.186

5.  Developmental programming of the metabolic syndrome - critical windows for intervention.

Authors:  Mark H Vickers
Journal:  World J Diabetes       Date:  2011-09-15

Review 6.  Small molecule epigenetic inhibitors targeted to histone lysine methyltransferases and demethylases.

Authors:  Zhanxin Wang; Dinshaw J Patel
Journal:  Q Rev Biophys       Date:  2013-09-02       Impact factor: 5.318

Review 7.  Targeting epigenetic mechanisms for chronic visceral pain: A valid approach for the development of novel therapeutics.

Authors:  Tijs Louwies; Casey O Ligon; Anthony C Johnson; Beverley Greenwood-Van Meerveld
Journal:  Neurogastroenterol Motil       Date:  2018-11-04       Impact factor: 3.598

8.  Divalproex sodium vs placebo for the treatment of irritability in children and adolescents with autism spectrum disorders.

Authors:  Eric Hollander; William Chaplin; Latha Soorya; Stacey Wasserman; Sherry Novotny; Jade Rusoff; Nicole Feirsen; Lauren Pepa; Evdokia Anagnostou
Journal:  Neuropsychopharmacology       Date:  2009-12-09       Impact factor: 7.853

Review 9.  Targeting deregulated epigenetic control in cancer.

Authors:  Sayyed K Zaidi; Andre J Van Wijnen; Jane B Lian; Janet L Stein; Gary S Stein
Journal:  J Cell Physiol       Date:  2013-11       Impact factor: 6.384

Review 10.  Understanding and determining the etiology of autism.

Authors:  Salvatore A Currenti
Journal:  Cell Mol Neurobiol       Date:  2009-09-23       Impact factor: 5.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.